WO2009043106A1 - Sélénium inorganique et angiogenèse - Google Patents

Sélénium inorganique et angiogenèse Download PDF

Info

Publication number
WO2009043106A1
WO2009043106A1 PCT/AU2008/001469 AU2008001469W WO2009043106A1 WO 2009043106 A1 WO2009043106 A1 WO 2009043106A1 AU 2008001469 W AU2008001469 W AU 2008001469W WO 2009043106 A1 WO2009043106 A1 WO 2009043106A1
Authority
WO
WIPO (PCT)
Prior art keywords
selenate
pharmaceutically acceptable
acceptable salt
cells
huvec
Prior art date
Application number
PCT/AU2008/001469
Other languages
English (en)
Inventor
Niall Corcoran
Christopher Hovens
Original Assignee
Velacor Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velacor Therapeutics Pty Ltd filed Critical Velacor Therapeutics Pty Ltd
Publication of WO2009043106A1 publication Critical patent/WO2009043106A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B19/00—Selenium; Tellurium; Compounds thereof
    • C01B19/008—Salts of oxyacids of selenium or tellurium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention porte d'une manière générale sur l'utilisation d'une quantité supranutritionnelle de sélénate ou de ses sels pharmaceutiquement acceptables, dans des procédés et compositions pour inhiber une angiogenèse non tumorale. La présente invention porte également sur l'utilisation de sélénate ou d'un sel pharmaceutiquement acceptable de celui-ci dans des procédés de traitement ou de prévention de maladies ou troubles non tumoraux associés à une angiogenèse aberrante, telle que la dégénérescence maculaire liée à l'âge. De plus, la présente invention porte sur l'utilisation de sélénate ou d'un sel pharmaceutiquement acceptable de celui-ci en association avec au moins un autre agent anti-angiogénique dans des procédés et compositions pour traiter ou prévenir des maladies ou troubles non tumoraux associés à une angiogenèse aberrante.
PCT/AU2008/001469 2007-10-03 2008-10-03 Sélénium inorganique et angiogenèse WO2009043106A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99766607P 2007-10-03 2007-10-03
US60/997,666 2007-10-03

Publications (1)

Publication Number Publication Date
WO2009043106A1 true WO2009043106A1 (fr) 2009-04-09

Family

ID=40525772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2008/001469 WO2009043106A1 (fr) 2007-10-03 2008-10-03 Sélénium inorganique et angiogenèse

Country Status (1)

Country Link
WO (1) WO2009043106A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110917209A (zh) * 2019-12-31 2020-03-27 彭咏波 含硒化合物或硒纳米在制备治疗关节炎药物的注射剂或微针中的用途

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512977A (en) * 1979-10-18 1985-04-23 Lundy Research Laboratories, Inc. Therapeutic selenium compositions and the use thereof
US5102910A (en) * 1989-05-11 1992-04-07 Homosan Ag Pharmaceutical preparation and method of treatment for liver dysfunction
US5925349A (en) * 1992-09-11 1999-07-20 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
WO2003066071A1 (fr) * 2002-02-07 2003-08-14 Laxdale Limited Formulations comprenant des medicaments psychotropes et du selenium
US20040131702A1 (en) * 2001-02-13 2004-07-08 Jaroslaw Lampe Use of selenite or preparation containing selenite for treating wounds
WO2005013951A2 (fr) * 2003-08-11 2005-02-17 Pomeranian Academy Of Medicine Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire
US20050048134A1 (en) * 2001-12-04 2005-03-03 Bodo Kuklinski Use of selenite-containing compounds to be topically or buccally administered
WO2005041955A1 (fr) * 2003-10-20 2005-05-12 Barrier Therapeutics, Inc. Methodes de traitement de troubles dermiques inflammatoires non microbiens
WO2006032074A1 (fr) * 2004-09-21 2006-03-30 Velacor Therapeutics Pty Ltd Sélénium inorganique pour le traitement du cancer
WO2007005670A2 (fr) * 2005-06-30 2007-01-11 The Research Foundation Of The State University Of New York Analogues de soufre et de selenium naturels et synthetiques, et leurs formes conjuguees polymeres, pour la modulation de l'angiogenese
WO2007109853A1 (fr) * 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Sélénium inorganique utilisé pour traiter des tumeurs bénines
WO2007109851A1 (fr) * 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Traitement de maladies neurodegénératives
WO2007130575A2 (fr) * 2006-05-03 2007-11-15 Florida Atlantic University Protection contre les dégâts oxydatifs dans des cellules

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512977A (en) * 1979-10-18 1985-04-23 Lundy Research Laboratories, Inc. Therapeutic selenium compositions and the use thereof
US5102910A (en) * 1989-05-11 1992-04-07 Homosan Ag Pharmaceutical preparation and method of treatment for liver dysfunction
US5925349A (en) * 1992-09-11 1999-07-20 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US20040131702A1 (en) * 2001-02-13 2004-07-08 Jaroslaw Lampe Use of selenite or preparation containing selenite for treating wounds
US20050048134A1 (en) * 2001-12-04 2005-03-03 Bodo Kuklinski Use of selenite-containing compounds to be topically or buccally administered
WO2003066071A1 (fr) * 2002-02-07 2003-08-14 Laxdale Limited Formulations comprenant des medicaments psychotropes et du selenium
WO2005013951A2 (fr) * 2003-08-11 2005-02-17 Pomeranian Academy Of Medicine Compositions pharmaceutiques et methodes permettant de prevenir le cancer du sein et de l'ovaire
WO2005041955A1 (fr) * 2003-10-20 2005-05-12 Barrier Therapeutics, Inc. Methodes de traitement de troubles dermiques inflammatoires non microbiens
WO2006032074A1 (fr) * 2004-09-21 2006-03-30 Velacor Therapeutics Pty Ltd Sélénium inorganique pour le traitement du cancer
WO2007005670A2 (fr) * 2005-06-30 2007-01-11 The Research Foundation Of The State University Of New York Analogues de soufre et de selenium naturels et synthetiques, et leurs formes conjuguees polymeres, pour la modulation de l'angiogenese
WO2007109853A1 (fr) * 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Sélénium inorganique utilisé pour traiter des tumeurs bénines
WO2007109851A1 (fr) * 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Traitement de maladies neurodegénératives
WO2007130575A2 (fr) * 2006-05-03 2007-11-15 Florida Atlantic University Protection contre les dégâts oxydatifs dans des cellules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHENONE, S. ET AL.: "Anti-angiogenic Agents: An Update on Small Molecule VEGFR Inhibitors", CURRENT MEDICINAL CHEMISTRY, vol. 14, no. 23, 2007, pages 2495 - 2516 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110917209A (zh) * 2019-12-31 2020-03-27 彭咏波 含硒化合物或硒纳米在制备治疗关节炎药物的注射剂或微针中的用途

Similar Documents

Publication Publication Date Title
Carr et al. Evidence of increased dopamine receptor signaling in food-restricted rats
Beckel et al. Pannexin 1 channels mediate the release of ATP into the lumen of the rat urinary bladder
Cuddapah et al. Bradykinin-induced chemotaxis of human gliomas requires the activation of KCa3. 1 and ClC-3
Karthikeyan et al. Gold nanoparticles downregulate VEGF-and IL-1β-induced cell proliferation through Src kinase in retinal pigment epithelial cells
US10993919B2 (en) Chondroprotective nanoparticles for the treatment of osteoarthritis
Lomonaco et al. Cilengitide induces autophagy-mediated cell death in glioma cells
Negrão et al. Different effects of catechin on angiogenesis and inflammation depending on VEGF levels
Wertheimer et al. EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model
Bello et al. Insights into intestinal regeneration signaling mechanisms
Yu et al. Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension
CN102811622A (zh) 用于治疗腱病的血小板衍生生长因子组合物和方法
Huang et al. Dynamic regulation of delta-opioid receptor in rat trigeminal ganglion neurons by lipopolysaccharide-induced acute pulpitis
Zhao et al. MC4R is involved in neuropathic pain by regulating JNK signaling pathway after chronic constriction injury
Wanigasekara et al. Neurturin has multiple neurotrophic effects on adult rat sacral parasympathetic ganglion neurons
Flores et al. Gastrin-releasing peptide receptors regulate proliferation of C6 glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism
Takeda et al. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor
CN112972508A (zh) 黄蜀葵花提取物作为trpc离子通道抑制剂的用途
WO2009043106A1 (fr) Sélénium inorganique et angiogenèse
Cao et al. Inhibition of acid sensing ion channel 3 aggravates seizures by regulating NMDAR function
CN111991408B (zh) 槲皮素-3-o-刺槐糖苷作为钙离子通道的抑制剂的应用
CN112891354B (zh) MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用
Hong et al. Silencing platelet‑derived growth factor receptor‑β enhances the radiosensitivity of C6 glioma cells in vitro and in vivo
EP3323411B1 (fr) Composition pour l'inhibition de l'angiogenèse contenant un complexe de nanoparticule-protéine du corps vitré en tant que substance active, et utilisation de celle-ci
Ding et al. Effects of PI3K/AKT/mTOR pathway regulation of HIF-1α on Lanthanum-induced neurotoxicity in rats
Haase et al. New retinoblastoma (RB) drug delivery approaches: anti‐tumor effect of atrial natriuretic peptide (ANP)‐conjugated hyaluronic‐acid‐coated gold nanoparticles for intraocular treatment of chemoresistant RB

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08800104

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08800104

Country of ref document: EP

Kind code of ref document: A1